Who owns Arcutis Biotherapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ARQT from SEC Form 13F filings across 294 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 294 institutions disclosed 149.0M shares of Arcutis Biotherapeutics, Inc. worth $3.96B — about 113.7% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
294
13F holders
$3.96B
value, 2026 filers
113.7%
of shares outstanding (149.0M sh)
65
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ARQT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 19.2M | $506.7M | 0.0% | 14.6% | +81.8% |
| 2 | MONTANOVA CAPITAL, LLC | 12.3M | $324.3M | 7.5% | 9.4% | -1.4% |
| 3 | Frazier Life Sciences Management, L.P. | 9.9M | $261.0M | 6.5% | 7.5% | 0.0% |
| 4 | Rubric Capital Management LP | 8.4M | $222.6M | 2.1% | 6.4% | +1.8% |
| 5 | STATE STREET CORP | 7.7M | $204.0M | 0.0% | 5.9% | +32.6% |
| 6 | Polar Capital Holdings Plc | 6.6M | $174.2M | 0.4% | 5% | -0.2% |
| 7 | UBS Group AG | 5.5M | $146.2M | 0.0% | 4.2% | +66.0% |
| 8 | MORGAN STANLEY | 5.3M | $140.0M | 0.0% | 4% | +19.0% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 5.0M | $132.0M | 0.0% | 3.8% | +0.1% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8M | $100.9M | 0.0% | 2.9% | +57.2% |
| 11 | BANK OF AMERICA CORP /DE/ | 3.5M | $92.3M | 0.0% | 2.7% | +17.0% |
| 12 | JENNISON ASSOCIATES LLC | 3.3M | $88.1M | 0.1% | 2.5% | -21.0% |
| 13 | ORBIMED ADVISORS LLC | 3.1M | $82.5M | 1.5% | 2.4% | +52.9% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 3.0M | $78.5M | 0.0% | 2.3% | -0.4% |
| 15 | D. E. Shaw & Co., Inc. | 2.6M | $69.9M | 0.0% | 2% | -33.0% |
| 16 | FRANKLIN TEMPLETON INC | 2.0M | $67.4M | 0.0% | 1.5% | +2.4% |
| 17 | AMERICAN CENTURY COMPANIES INC | 2.0M | $52.2M | 0.0% | 1.5% | +2.6% |
| 18 | GOLDMAN SACHS GROUP INC | 1.6M | $43.6M | 0.0% | 1.3% | -1.2% |
| 19 | INFINITUM ASSET MANAGEMENT, LLCNEW | 1.6M | $42.3M | 3.7% | 1.2% | new |
| 20 | CITADEL ADVISORS LLC | 1.5M | $40.5M | 0.0% | 1.2% | +32.0% |
| 21 | OBERWEIS ASSET MANAGEMENT INC/ | 1.5M | $40.2M | 0.9% | 1.2% | +10.8% |
| 22 | Janus Henderson Group Ltd.NEW | 1.4M | $35.9M | 0.0% | 1% | new |
| 23 | GW&K Investment Management, LLC | 1.4M | $35.7M | 0.3% | 1% | +5.0% |
| 24 | BAMCO INC /NY/ | 1.2M | $32.2M | 0.1% | 0.9% | -2.8% |
| 25 | Aberdeen Group plc | 1.2M | $31.8M | 0.0% | 0.9% | +9.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.